The role of CD74 in cardiovascular disease

Qiu-Lin Li; Jing Tang; Ling Zhao; Amanguli Ruze; Xue-Feng Shan; Xiao-Ming Gao

doi:10.3389/fcvm.2022.1049143

The role of CD74 in cardiovascular disease

Front Cardiovasc Med. 2023 Jan 12:9:1049143. doi: 10.3389/fcvm.2022.1049143. eCollection 2022.

Authors

Qiu-Lin Li^{1

2}, Jing Tang^{1

2

3}, Ling Zhao^{1

2}, Amanguli Ruze^{1

2}, Xue-Feng Shan^{1

2}, Xiao-Ming Gao^{1

2

4}

Affiliations

¹ State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asian, Department of Cardiology, The First Affiliated Hospital of Xinjiang Medical University, Ürümqi, China.
² Xinjiang Key Laboratory of Medical Animal Model Research, Ürümqi, China.
³ Department of Clinical Laboratory, The First Affiliated Hospital of Xinjiang Medical University, Ürümqi, China.
⁴ Clinical Medical Research Institute of Xinjiang Medical University, Ürümqi, China.

Abstract

Leukocyte differentiation antigen 74 (CD74), also known as invariant chain, is a molecular chaperone of major histocompatibility complex class II (MHC II) molecules involved in antigen presentation. CD74 has recently been shown to be a receptor for the macrophage migration inhibitory factor family proteins (MIF/MIF2). Many studies have revealed that CD74 plays an important role in cardiovascular disease. In this review, we summarize the structure and main functions of CD74 and then focus on the recent research progress on the role of CD74 in cardiovascular diseases. In addition, we also discuss potential treatment strategies that target CD74. Our systematic review of the role of CD74 in cardiovascular disease will fill some knowledge gaps in the field.

Keywords: CD74; D-DT/MIF2; MIF; cardiovascular diseases; invariant chain.

Publication types

Review

Grants and funding

This work was supported by grants of the Natural Science Foundation of China (Nos. U1903212 and 81870272), Xinjiang University Scientific Research Project (XJEDU2019I018), Opening Project of the Xinjiang Key Laboratory (2021D04020), and the State Key Laboratory of Pathogenesis, Prevention and Treatment of Central Asia High Incidence Diseases fund (SKL-HIDCA-2021-XXG1).